title: The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program.
abstract: The Society for Immunotherapy of Cancer, SITC (formerly the International Society for Biological Therapy of Cancer, iSBTc), aims to improve cancer patient outcomes by advancing the science, development and application of biological therapy and immunotherapy. The society and its educational programs have become premier destinations for interaction and innovation in the cancer biologics community. For over a decade, the society has offered the Primer on Tumor Immunology and Biological Therapy of Cancer™ in conjunction with its Annual Scientific Meeting. This report summarizes the 2010 Primer that took place October 1, 2010 in Washington, D.C. as part of the educational offerings associated with the society's 25th anniversary. The target audience was basic and clinical investigators from academia, industry and regulatory agencies, and included clinicians, post-doctoral fellows, students, and allied health professionals. Attendees were provided a review of basic immunology and educated on the current status and most recent advances in tumor immunology and clinical/translational cancer immunology. Ten prominent investigators presented on the following topics: innate immunity and inflammation; an overview of adaptive immunity; dendritic cells; tumor microenvironment; regulatory immune cells; immune monitoring; cytokines in cancer immunotherapy; immune modulating antibodies; cancer vaccines; and adoptive T cell therapy. Presentation slides, a Primer webinar and additional program information are available online on the society's website.
authors.affiliation: Society for Immunotherapy of Cancer, Milwaukee, WI, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: Balwit
authors.forename: Patrick
authors.initials: P
authors.lastname: Hwu
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Urba
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
mesh_terms: D056704:Adaptive Immunity / Q000502:physiology; D001688:Biological Products / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods* / Q000639:trends; D006801:Humans; D007167:Immunotherapy / Q000331:legislation & jurisprudence / Q000379:methods; D007391:International Cooperation; D008495:Medical Oncology / Q000193:education* / Q000331:legislation & jurisprudence / Q000458:organization & administration / Q000639:trends*; D009369:Neoplasms / Q000628:therapy*; D012955:Societies, Medical / Q000331:legislation & jurisprudence / Q000458:organization & administration; D059016:Tumor Microenvironment / Q000502:physiology
chemical_list: D001688:Biological Products